The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe - four times that of Italy or the Netherlands. This is unsurprising, considering many patients still rely on their blue inhalers alone.

The Primary Care Respiratory Society (PCRS) and Asthma + Lung UK call for urgent action to address the growing number of online pharmacies selling salbutamol inhalers without appropriate medical oversight.

The webinar will be held on Friday 9 May 2025 at 19:00 for 45 minutes. Chaired by Katherine Hickman (our PCRS Executive Chair), she and guest speakers, Deborah Leese and Marieke Strange, will focus on:

2024 marked a pivotal change in the management of asthma in the UK with the publication of a joint British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guideline.

The NHS is under increased financial and environmental pressures. Blanket switching of medications (changing medication from one to another without patient consultation) to more cost-effective and environmentally friendly options is therefore becoming more common. 

Let's be MART for asthma.

Now is the time to make MART moves for asthma. 

Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers. 

Be proactive, not reactive.

Inhalation is the main route for administration of drugs for conditions such as asthma or chronic obstructive pulmonary disease. The advantage of administering drugs by inhaler is that drugs are delivered directly to the site of action within the airways.

The webinar will be held on Wednesday 9th October 2024 at 19:00 for 45 minutes. Chaired by Katherine Hickman (our PCRS Executive Chair), she and guest speaker, Noreen Grant (GP), will focus on:

Concerns about the environmental impact of the propellant gases used in pressurised metered dose inhalers (pMDIs) and the plastics used in all single-use inhaler devices have made them an important focus for efforts to reduce the environmental impact of the NHS.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/beta-agonist) combination treatment to be prescribed as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an